8:11AM Rexahn Pharmaceuticals announces publication of new preclinical research data for novel anti-cancer compound RX-3117 (RNN) 0.40 : The data demonstrates the synthesis of RX-3117 and its 2'-deoxy analogue, as well as its in vitro cell-line activity and strong in vivo anti-tumor effect. "This study provides further evidence of RX-3117's potential as an anti-cancer compound," said Rick Soni, President of Rexahn. "In the preclinical study, RX-3117 significantly inhibited growth of human cancer cells in vitro and the growth of tumors in in vivo models of nude mice."
Market Data 
Markets 
AI
